226 related articles for article (PubMed ID: 35086552)
1. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
[TBL] [Abstract][Full Text] [Related]
2. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
3. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
6. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
8. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
9. The SF3B1
Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
[TBL] [Abstract][Full Text] [Related]
10. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
[TBL] [Abstract][Full Text] [Related]
12. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Choudhary GS; Pellagatti A; Agianian B; Smith MA; Bhagat TD; Gordon-Mitchell S; Sahu S; Pandey S; Shah N; Aluri S; Aggarwal R; Aminov S; Schwartz L; Steeples V; Booher RN; Ramachandra M; Samson M; Carbajal M; Pradhan K; Bowman TV; Pillai MM; Will B; Wickrema A; Shastri A; Bradley RK; Martell RE; Steidl UG; Gavathiotis E; Boultwood J; Starczynowski DT; Verma A
Elife; 2022 Aug; 11():. PubMed ID: 36040792
[TBL] [Abstract][Full Text] [Related]
13. Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence.
Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Montero-Hidalgo AJ; Martín-Colom J; Doval-Rosa C; Blanco-Acevedo C; Torres E; Toledano-Delgado Á; Sánchez-Sánchez R; Peralbo-Santaella E; Ortega-Salas RM; Jiménez-Vacas JM; Tena-Sempere M; López M; Castaño JP; Gahete MD; Solivera J; Luque RM
EBioMedicine; 2023 Apr; 90():104484. PubMed ID: 36907105
[TBL] [Abstract][Full Text] [Related]
14. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
[TBL] [Abstract][Full Text] [Related]
15. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation.
Popli P; Richters MM; Chadchan SB; Kim TH; Tycksen E; Griffith O; Thaker PH; Griffith M; Kommagani R
Cell Death Dis; 2020 Oct; 11(10):842. PubMed ID: 33040078
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin Receptor Splicing Variant
Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
[TBL] [Abstract][Full Text] [Related]
17. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
[TBL] [Abstract][Full Text] [Related]
18. SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.
Xu T; Li X; Zhao W; Wang X; Jin L; Feng Z; Li H; Zhang M; Tian Y; Hu G; Yue Y; Dai X; Shan C; Zhang W; Zhang C; Zhang Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):126. PubMed ID: 38671459
[TBL] [Abstract][Full Text] [Related]
19. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
20. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
Kim Guisbert KS; Mossiah I; Guisbert E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
